Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Myelofibrosis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.3
6 insiders sold shares within a month
Since May 14, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 353 (final count)
- Started
- Mar 11, 2021
- Main results expected
- Feb 20, 2026
- Fully finished
- Mar 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan
Measured over: At Week 24
Phase 3: Absolute mean change in TSS (Abs-TSS) from baseline to Week 24 as measured by the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0
Measured over: At Week 24
Phase 1: Maximum Tolerated Dose (MTD)
Measured over: Approximately within the first cycle (28 days) of therapy
Phase 1: Recommended Phase 2 Dose (RP2D)
Measured over: Approximately within the first cycle (28 days) of therapy
Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity
Measured over: From start of drug administration up to 30 days after last dose of study treatment (approximately 48 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.3, since 2026-05-14, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04562389 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC